Indian Cancer Genome Atlas Launches India’s first comprehensive cancer data portal – Healthcare News

The Indian Cancer Genome Atlas (ICGA) on Saturday announced that it has launched India’s first comprehensive cancer multi-omics data portal. This pioneering platform provides open access to clinically correlated data from Indian cancer patients, aimed at transforming cancer research and treatment for Indian populations, the organisation claimed.

Historically, cancer treatments in India have been based on Western data sets. However, cancers in Indian patients can differ significantly at the molecular level. ICGA’s mission is to create Indian-specific datasets to help researchers and clinicians develop personalized treatment protocols. This new open-access portal represents a monumental step in revolutionizing cancer research, specifically for Indian patients.

The ICGA cancer multi-omics portal is the first in India to offer data that includes DNA, RNA, and protein profiles of breast cancer patients, integrated with clinical outcomes. Currently, the platform consists of data from 50 breast cancer patients, with plans to expand to over 500 patients in the coming year.

Roblox set to launch paid videogames on its virtual platform

Kalindi Express traveling from Prayagraj to Bhiwani hits LPG cylinder on tracks, derailment averted: Police

YouTube’s new family center feature: How parents can monitor teens’ channel activity

UPSC gets permit to carry out Aadhaar-based authentication of candidates on voluntary basis

Key Highlights of this portal include:

• India’s First Cancer Multi-Omics Data Portal: A comprehensive resource that offers detailed multi-omics data for breast cancer patients, including genomic and proteomic information.
• Based on cBioPortal Platform: Derived from the internationally recognized cBioPortal, this platform ensures seamless integration with global cancer research efforts.
• Initial Dataset from 50 Indian Patients: Provides clinically annotated DNA, RNA, and protein profiles, along with treatment histories and patient outcomes, with an aim to scale up to 500 in a year.
• Free Access Under PRIDE Guidelines: Adhering to responsible and ethical data-sharing practices, the portal is freely accessible to the scientific community.
• A Step Toward Precision Oncology for Indian Patients: This initiative is designed to enable the development of personalized cancer treatments tailored to Indian patients.
• Call for Collaboration: ICGA invites researchers worldwide to contribute and expand the platform, fostering global collaboration in cancer research.

In a joint statement, Dr JC Zenklusen – Director of The Cancer Genome Atlas (TCGA) at the NCI, NIH, USA, and Prof Sunil Badve – Vice Chair, Pathology Cancer Programs, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA said that 15 years ago, when we launched TCGA, we could not have foreseen the remarkable progress cancer research would make.

“It is incredibly exciting to see ICGA advancing so rapidly and taking bold steps in revolutionizing cancer research. Understanding the genome of cancer patients will improve the treatment of Indians not only in India but also worldwide. We, both, encourage others with similar data to actively contribute to ICGA, so this initiative can grow even faster and drive greater breakthroughs,” they said.

This data is freely accessible to the global research community under India’s PRIDE guidelines, which promote ethical sharing and collaboration in cancer research, it stated

“We have made an excellent start with this groundbreaking multi-omics cancer portal. Cancer touches all of us, and the need for more effective, personalized treatments—especially tailored to the unique genetic and environmental factors in India—is urgent. This portal will empower researchers with crucial data to advance customized cancer research for better treatment outcomes. I encourage everyone to contribute and support this vital cause, helping us accelerate progress in the fight against cancer,” Dr. Anand Deshpande, Chairman and Managing Director at Persistent, and Non-Executive Director at ICGA said in a statement.

_{Images are for reference only.Images and contents gathered automatic from google or 3rd party sources.All rights on the images and contents are with their original owners.}